Cimzia — Cigna
Spondyloarthritis, Other Subtypes (e.g., undifferentiated arthritis, reactive arthritis)
Initial criteria
- Patient age ≥ 18 years
- Patient has arthritis primarily in the knees, ankles, elbows, wrists, hands, and/or feet
- Patient has tried at least ONE conventional synthetic DMARD (e.g., methotrexate, leflunomide, sulfasalazine)
- Medication is prescribed by or in consultation with a rheumatologist
Reauthorization criteria
- Patient has been established on the requested drug for at least 6 months
- Patient meets ONE of the following: a) beneficial clinical response by at least one objective measure (e.g., ASDAS or lab markers); OR b) improvement from baseline in at least one symptom such as decreased pain or stiffness or improved function
Approval duration
initial 6 months, renewal 1 year